Literature DB >> 16379433

Oral health needs of the head and neck radiotherapy patient: 2. Oral and dental care before, during and after radiotherapy.

Osama Omer1, Denise MacCarthy, June Nunn, Edward Cotter.   

Abstract

UNLABELLED: Head and neck cancer represents a heterogeneous group of neoplasms affecting a number of sites in the aerodigestive tract, histologically primarily epithelial in type. Most are sensitive to a treatment regime of ablative surgery followed by radiotherapy. The incidence of head and neck cancers is approximately 11.8 per 100,000 population and is the 8th commonest cancer in males and the 16th in females. Treatment comprises ablative surgery with, in 60% of cases, radiotherapy. The oral and dental sequelae of such treatment, and their management, is described. CLINICAL RELEVANCE: Many of these cancers will manifest with oral signs and symptoms, thus placing the GDP in the unique position of being able to detect and positively influence outcomes. As well, the GDP has a vital, proactive role to play in supportive care before, during and following surgery and radiotherapy.

Entities:  

Mesh:

Year:  2005        PMID: 16379433     DOI: 10.12968/denu.2005.32.10.575

Source DB:  PubMed          Journal:  Dent Update        ISSN: 0305-5000


  3 in total

1.  A national survey of restorative consultants' treatment provision for head and neck oncology patients.

Authors:  G Calvert; S C Barclay; J S Owens; A Alani
Journal:  Br Dent J       Date:  2014-11       Impact factor: 1.626

2.  Oral Rehabilitation in Irradiated Patients: Implant- or Tooth-Supported Fixed Prosthesis? A Clinical Report.

Authors:  Somayeh Allahyari
Journal:  Front Dent       Date:  2019-08-30

3.  Dental therapy before and after radiotherapy--an evaluation on patients with head and neck malignancies.

Authors:  Sabine Sennhenn-Kirchner; Friederike Freund; Sven Grundmann; Alexios Martin; Margarete Borg-von Zepelin; Hans Christiansen; Hendrik Andreas Wolff; Hans-Georg Jacobs
Journal:  Clin Oral Investig       Date:  2008-10-17       Impact factor: 3.573

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.